Nova Biomedical Canada Ltd. Industry Workshop

Session Title:
Management of dysglycemia in critically ill patients - recent FDA clearances & consequences

Presenters:
Wei Qiu, Nova Biomedical

Objectives:
At the conclusion of this session, participants will be able to:
1. Review FDA historical background for BGMS
2. Review evolution of StatStrip labelling changes and clearances
3. Review study design for arterial and venous claim
4. Review FDA Advisory Panel presentation
5. Review study design for capillary claim
6. Review FDA device classifications
7. Summarize implications for use

Question Title

* 1. Please rate the Session by circling the appropriate number:
Rating Scale:1 Strongly Disagree, 2 Disagree, 3 Neutral, 4 Agree, 5 Strongly Agree

  1 2 3 4 5
Sufficient time was allowed for audience participation/active learning
The facilities were satisfactory.
The session was free from commercial bias
Overall, I would rate this Symposium as excellent

Question Title

* 2. Please asses the Speaker by circling the appropriate number.
Rating Scale: 1 Poor, 2 Fair, 3 Good, 4 Very Good, 5 Outstanding
Wei Qiu, Nova Biomedical

  1 2 3 4 5
Clarity of
Met Stated Objectives
Balanced & Unbiased
Relevant to Practice Overall
Time for Active Learning

Question Title

* 3. As a result of attending this session, I am planning to: (please check one)

  YES NO
a) Discuss the session with my colleagues
b) Pursue additional learning activities.
c) Complete a Personal Learning Project.
d) Not change my practice.
e) Change my practice.

Question Title

* 4. Please explain the change you are planning to make or the learning you plan to complete:

Question Title

* 5. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Question Title

* 6. General comments about individual speakers

Question Title

* 7. What topics need to be addressed at future conferences to keep you up to date in your profession?

T